Study questions anti-cancer mechanisms of drug tested in clinical trials

The diabetes drug metformin is being tested in numerous clinical trials for treating different cancers, and several studies point to its apparent activation of a molecular regulator of cell metabolism called AMPK to suppress tumor growth. But new research suggests that activation of AMPK may fuel cancer growth, and that clinicians testing the drug should re-evaluate their data.